Latent HIV May Exist in Both Resting and Non-Resting CD4 T cells
Researchers quantify inducible virus in long-term suppressed patients that was missed by the gold standard assay that measures the latent reservoir.
CROI 2017
New Study Links Darunavir to Increased Risk for CVD
Study looking at the use of 2 frequently used protease inhibitors (atazanavir and darunavir) is suggesting that cumulative use of darunavir may be independently associated with a small but gradually increasing cardiovascular disease (CVD) risk.
Novel mRNA Zika Virus Vaccine Shows Rapid and Durable Protection
A new vaccine candidate uses an mRNA platform to deliver safe, low doses of a vaccine that offers high levels of sustained protection against Zika virus.
Investigational 2-Drug HIV Regimen Showing Promise
Investigational combination of a once-daily 2-drug regimen of dolutegravir plus rilpivirine may be as effective as a 3- or 4-drug current antiretroviral regimen in HIV-1-infected patients.
Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential
Viral loads can fluctuate over time depending on patients’ access and response to HIV treatment, their medication adherence behavior, and care status.
Potential New Drug Option for Treatment-Naïve HIV-1 Patients
The once-daily dosing doravirine appears to have similar efficacy and to be non-inferior to once-daily ritonavir-boosted darunavir (DRV+r) on a background of 2 NRTIs in HIV-1 treatment-naïve adults.
Study Supports Current Prevention Interventions for Zika Exposure
The current sexual prevention guidelines recommend that men use condoms or abstain from sex for 6 months after Zika virus exposure. Now there are strong data to support these guidelines.
Advances in the Battle Against HIV/AIDS to be Highlighted at CROI 2017
Vaccines against HIV/AIDS enter a new era.
Want to read more?
Please login or register first to view this content.
Next post in CROI 2017
